Aptevo Therapeutics Ownership 2024 | Who Owns Aptevo Therapeutics Now?


OverviewRevenueFinancialsChart

Institutional Ownership

15.37%

Insider Ownership

0.10%

Retail Ownership

84.53%

Institutional Holders

30.00

Aptevo Therapeutics Institutional Shareholders


Institutional Shareholders by % of Total Shares

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
JPMORGAN CHASE & CO----1,897-100.00%-Mar 31, 2024
FIFTH THIRD BANCORP----291-100.00%-Mar 31, 2024
FRANKLIN RESOURCES INC----10,997-100.00%-Mar 31, 2024
BANK OF AMERICA CORP /DE/----6-100.00%-Mar 31, 2024
WELLS FARGO & COMPANY/MN----1,617-100.00%-Mar 31, 2024
NORTHERN TRUST CORP----14,121-100.00%-Mar 31, 2024
STATE STREET CORP----10,941-100.00%-Mar 31, 2024
VANGUARD GROUP INC----91,725-100.00%-Mar 31, 2024
PNC FINANCIAL SERVICES GROUP, INC.----142-100.00%-Mar 31, 2024
CITIGROUP INC----10-100.00%-Mar 31, 2024
MORGAN STANLEY----11,370-100.00%-Mar 31, 2024
CANTOR FITZGERALD, L. P.----58,532-100.00%-Mar 31, 2024
RENAISSANCE TECHNOLOGIES LLC----516,789-100.00%-Mar 31, 2024
GEODE CAPITAL MANAGEMENT, LLC----43,201-100.00%-Mar 31, 2024
MILLENNIUM MANAGEMENT LLC----104,608-100.00%-Mar 31, 2024
BLACKROCK INC.----46,635-100.00%-Mar 31, 2024
CITADEL ADVISORS LLC----262,124-100.00%-Mar 31, 2024
TWO SIGMA SECURITIES, LLC----11,248-100.00%-Mar 31, 2024
ALYESKA INVESTMENT GROUP, L.P.----45,980-100.00%-Mar 31, 2024
TOWER RESEARCH CAPITAL LLC (TRC)----13,660-100.00%-Mar 31, 2024

Aptevo Therapeutics's largest institutional shareholder is JPMORGAN CHASE & CO, holding 0.00% of the company's total share outstanding, currently valued at -. The top 10 institutional shareholders own together 0.00% of the company.

Institutional Shareholders by % of Total Assets

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
JPMORGAN CHASE & CO----1,897-100.00%-Mar 31, 2024
FIFTH THIRD BANCORP----291-100.00%-Mar 31, 2024
FRANKLIN RESOURCES INC----10,997-100.00%-Mar 31, 2024
BANK OF AMERICA CORP /DE/----6-100.00%-Mar 31, 2024
WELLS FARGO & COMPANY/MN----1,617-100.00%-Mar 31, 2024
NORTHERN TRUST CORP----14,121-100.00%-Mar 31, 2024
STATE STREET CORP----10,941-100.00%-Mar 31, 2024
VANGUARD GROUP INC----91,725-100.00%-Mar 31, 2024
PNC FINANCIAL SERVICES GROUP, INC.----142-100.00%-Mar 31, 2024
CITIGROUP INC----10-100.00%-Mar 31, 2024
MORGAN STANLEY----11,370-100.00%-Mar 31, 2024
CANTOR FITZGERALD, L. P.----58,532-100.00%-Mar 31, 2024
RENAISSANCE TECHNOLOGIES LLC----516,789-100.00%-Mar 31, 2024
GEODE CAPITAL MANAGEMENT, LLC----43,201-100.00%-Mar 31, 2024
MILLENNIUM MANAGEMENT LLC----104,608-100.00%-Mar 31, 2024
BLACKROCK INC.----46,635-100.00%-Mar 31, 2024
CITADEL ADVISORS LLC----262,124-100.00%-Mar 31, 2024
TWO SIGMA SECURITIES, LLC----11,248-100.00%-Mar 31, 2024
ALYESKA INVESTMENT GROUP, L.P.----45,980-100.00%-Mar 31, 2024
TOWER RESEARCH CAPITAL LLC (TRC)----13,660-100.00%-Mar 31, 2024

The largest Aptevo Therapeutics shareholder by % of total assets is JPMORGAN CHASE & CO. The company owns 0.00 shares of Aptevo Therapeutics (APVO), representing 0.00% of its total assets.

Institutional Buyers

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
UBS GROUP AG----5-100.00%-Mar 31, 2024
BANK OF AMERICA CORP /DE/----6-100.00%-Mar 31, 2024
CITIGROUP INC----10-100.00%-Mar 31, 2024
ALLWORTH FINANCIAL LP----17-100.00%-Mar 31, 2024
ADVISOR GROUP HOLDINGS, INC.----30-100.00%-Mar 31, 2024
TRUVESTMENTS CAPITAL LLC----95-100.00%-Mar 31, 2024
PNC FINANCIAL SERVICES GROUP, INC.----142-100.00%-Mar 31, 2024
FIFTH THIRD BANCORP----291-100.00%-Mar 31, 2024
WELLS FARGO & COMPANY/MN----1,617-100.00%-Mar 31, 2024
JPMORGAN CHASE & CO----1,897-100.00%-Mar 31, 2024
DIVERGENT WEALTH ADVISORS----10,000-100.00%-Mar 31, 2024
STATE STREET CORP----10,941-100.00%-Mar 31, 2024
FRANKLIN RESOURCES INC----10,997-100.00%-Mar 31, 2024
TWO SIGMA SECURITIES, LLC----11,248-100.00%-Mar 31, 2024
MORGAN STANLEY----11,370-100.00%-Mar 31, 2024
TOWER RESEARCH CAPITAL LLC (TRC)----13,660-100.00%-Mar 31, 2024
NORTHERN TRUST CORP----14,121-100.00%-Mar 31, 2024
BAADER BANK AKTIENGESELLSCHAFT----15,086-100.00%-Mar 31, 2024
GEODE CAPITAL MANAGEMENT, LLC----43,201-100.00%-Mar 31, 2024
ALYESKA INVESTMENT GROUP, L.P.----45,980-100.00%-Mar 31, 2024

As of Mar 31 2024, Aptevo Therapeutics's largest institutional buyer is UBS GROUP AG. The company purchased -5.00 stocks of APVO, valued at -.

Institutional Sellers

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
RENAISSANCE TECHNOLOGIES LLC----516,789-100.00%-Mar 31, 2024
SABBY MANAGEMENT, LLC----349,471-100.00%-Mar 31, 2024
CITADEL ADVISORS LLC----262,124-100.00%-Mar 31, 2024
SCHONFELD STRATEGIC ADVISORS LLC----159,000-100.00%-Mar 31, 2024
SQUAREPOINT OPS LLC----138,697-100.00%-Mar 31, 2024
MILLENNIUM MANAGEMENT LLC----104,608-100.00%-Mar 31, 2024
VANGUARD GROUP INC----91,725-100.00%-Mar 31, 2024
ARMISTICE CAPITAL, LLC----61,130-100.00%-Mar 31, 2024
CANTOR FITZGERALD, L. P.----58,532-100.00%-Mar 31, 2024
BLACKROCK INC.----46,635-100.00%-Mar 31, 2024
ALYESKA INVESTMENT GROUP, L.P.----45,980-100.00%-Mar 31, 2024
GEODE CAPITAL MANAGEMENT, LLC----43,201-100.00%-Mar 31, 2024
BAADER BANK AKTIENGESELLSCHAFT----15,086-100.00%-Mar 31, 2024
NORTHERN TRUST CORP----14,121-100.00%-Mar 31, 2024
TOWER RESEARCH CAPITAL LLC (TRC)----13,660-100.00%-Mar 31, 2024
MORGAN STANLEY----11,370-100.00%-Mar 31, 2024
TWO SIGMA SECURITIES, LLC----11,248-100.00%-Mar 31, 2024
FRANKLIN RESOURCES INC----10,997-100.00%-Mar 31, 2024
STATE STREET CORP----10,941-100.00%-Mar 31, 2024
DIVERGENT WEALTH ADVISORS----10,000-100.00%-Mar 31, 2024

As of Mar 31 2024, Aptevo Therapeutics's biggest institutional seller is RENAISSANCE TECHNOLOGIES LLC. The company sold -0.52M shares of APVO, valued at -.

Institutional New positions

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate

Institutional Sold Out

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
RENAISSANCE TECHNOLOGIES LLC----516,789-100.00%-Mar 31, 2024
SABBY MANAGEMENT, LLC----349,471-100.00%-Mar 31, 2024
CITADEL ADVISORS LLC----262,124-100.00%-Mar 31, 2024
SCHONFELD STRATEGIC ADVISORS LLC----159,000-100.00%-Mar 31, 2024
SQUAREPOINT OPS LLC----138,697-100.00%-Mar 31, 2024
MILLENNIUM MANAGEMENT LLC----104,608-100.00%-Mar 31, 2024
VANGUARD GROUP INC----91,725-100.00%-Mar 31, 2024
ARMISTICE CAPITAL, LLC----61,130-100.00%-Mar 31, 2024
CANTOR FITZGERALD, L. P.----58,532-100.00%-Mar 31, 2024
BLACKROCK INC.----46,635-100.00%-Mar 31, 2024
ALYESKA INVESTMENT GROUP, L.P.----45,980-100.00%-Mar 31, 2024
GEODE CAPITAL MANAGEMENT, LLC----43,201-100.00%-Mar 31, 2024
BAADER BANK AKTIENGESELLSCHAFT----15,086-100.00%-Mar 31, 2024
NORTHERN TRUST CORP----14,121-100.00%-Mar 31, 2024
TOWER RESEARCH CAPITAL LLC (TRC)----13,660-100.00%-Mar 31, 2024
MORGAN STANLEY----11,370-100.00%-Mar 31, 2024
TWO SIGMA SECURITIES, LLC----11,248-100.00%-Mar 31, 2024
FRANKLIN RESOURCES INC----10,997-100.00%-Mar 31, 2024
STATE STREET CORP----10,941-100.00%-Mar 31, 2024
DIVERGENT WEALTH ADVISORS----10,000-100.00%-Mar 31, 2024
JPMORGAN CHASE & CO----1,897-100.00%-Mar 31, 2024
WELLS FARGO & COMPANY/MN----1,617-100.00%-Mar 31, 2024
FIFTH THIRD BANCORP----291-100.00%-Mar 31, 2024
PNC FINANCIAL SERVICES GROUP, INC.----142-100.00%-Mar 31, 2024
TRUVESTMENTS CAPITAL LLC----95-100.00%-Mar 31, 2024
ADVISOR GROUP HOLDINGS, INC.----30-100.00%-Mar 31, 2024
ALLWORTH FINANCIAL LP----17-100.00%-Mar 31, 2024
CITIGROUP INC----10-100.00%-Mar 31, 2024
BANK OF AMERICA CORP /DE/----6-100.00%-Mar 31, 2024
UBS GROUP AG----5-100.00%-Mar 31, 2024

Aptevo Therapeutics's largest sold out institutional shareholder by shares sold is RENAISSANCE TECHNOLOGIES LLC, sold -0.52M shares, valued at -, as of undefined.

Aptevo Therapeutics Mutual Fund Holders


Name% Total AssetsTotal SharesChange AmountChange %Date
BRIDGEWAY FUNDS INC0.03%83,802--Dec 29, 2023
T. Rowe Price Index Trust, Inc.0.00%46,200--Feb 29, 2024
VANGUARD INDEX FUNDS0.00%183,450-37,614-17.01%Dec 31, 2023
FIDELITY CONCORD STREET TRUST0.00%41,777--Feb 29, 2024
VANGUARD INSTITUTIONAL INDEX FUNDS0.00%2,287--Dec 31, 2023
SCHWAB CAPITAL TRUST0.00%1,654--Feb 29, 2024
Legg Mason Global Asset Management Trust0.00%13,113--Jan 31, 2024
Dimensional ETF Trust0.00%6,015--Jan 31, 2024
Legg Mason Global Asset Management Trust0.00%10,288--Jan 31, 2024
NORTHERN FUNDS0.00%5,531--Dec 29, 2023
DFA INVESTMENT DIMENSIONS GROUP INC0.00%3,470--Jan 31, 2024
SUNAMERICA SERIES TRUST0.00%709--Jan 31, 2024
EQ ADVISORS TRUST0.00%524--Dec 31, 2023
JOHN HANCOCK VARIABLE INSURANCE TRUST0.00%400--Dec 31, 2023

Aptevo Therapeutics's largest mutual fund holder by % of total assets is "BRIDGEWAY FUNDS INC", owning 83.80K shares, compromising 0.03% of its total assets.

Aptevo Therapeutics Institutional Ownership Trends


Institutional Holdings Trend

DateHoldingsChange %
31 Dec, 233015.38%
30 Sep, 232613.04%
30 Jun, 2323-
31 Mar, 2323-11.54%
31 Dec, 222630.00%
30 Sep, 2220-
30 Jun, 222017.65%
31 Mar, 2217-5.56%
31 Dec, 2118-14.29%
30 Sep, 2121-16.00%
30 Jun, 2125-24.24%
31 Mar, 2133-2.94%
31 Dec, 2034100.00%
30 Sep, 2017-10.53%
30 Jun, 201918.75%
31 Mar, 2016-

As of 31 Dec 23, 30 institutions are holding Aptevo Therapeutics's shares, representing an increase of 15.38% compared to the previous quarter.

Shares Outstanding Trend

DateShares OutstandingChange %
31 Dec, 231,933,445-43.29%
30 Sep, 233,409,316267.07%
30 Jun, 23928,8045.35%
31 Mar, 23881,596-8.48%
31 Dec, 22963,25011.08%
30 Sep, 22867,1499.03%
30 Jun, 22795,3370.40%
31 Mar, 22792,1904.13%
31 Dec, 21760,799-75.57%
30 Sep, 213,114,1055.20%
30 Jun, 212,960,2220.56%
31 Mar, 212,943,8531.18%
31 Dec, 202,909,605341.29%
30 Sep, 20659,3484.30%
30 Jun, 20632,18430.45%
31 Mar, 20484,601-

Aptevo Therapeutics (APVO) has 1.93M shares outstanding as of 31 Dec 23, down -43.29% compared to the previous quarter.

Institutional Ownership Trend

DateOwnership %Change %
31 Dec, 2315.37%0.56%
30 Sep, 2352.60%30.06%
30 Jun, 2313.23%8.39%
31 Mar, 2312.55%3.52%
31 Dec, 2218.89%6.51%
30 Sep, 2217.03%6.80%
30 Jun, 2215.83%6.15%
31 Mar, 2216.04%6.09%
31 Dec, 2116.23%0.40%
30 Sep, 2163.66%1.50%
30 Jun, 2165.25%1.47%
31 Mar, 2166.63%1.54%
31 Dec, 2065.85%15.83%
30 Sep, 2020.40%5.33%
30 Jun, 2019.56%8.90%
31 Mar, 2014.82%-

As of 31 Dec 23, Aptevo Therapeutics is held by 15.37% institutional shareholders, representing a 0.56% growth compared to 30 Sep 23.

Institutional Increased Positions Trend

DateIncreased PositionsChange %
31 Dec, 231233.33%
30 Sep, 23950.00%
30 Jun, 236-14.29%
31 Mar, 237-46.15%
31 Dec, 221344.44%
30 Sep, 229-
30 Jun, 22950.00%
31 Mar, 226-25.00%
31 Dec, 218-20.00%
30 Sep, 2110-23.08%
30 Jun, 2113-13.33%
31 Mar, 2115-44.44%
31 Dec, 2027237.50%
30 Sep, 208-11.11%
30 Jun, 209-43.75%
31 Mar, 2016-

12 institutional shareholders have increased their position in APVO stock as of 31 Dec 23 compared to 9 in the previous quarter (a 33.33% increase).

Institutional Reduced Positions Trend

DateReduced PositionsChange %
31 Dec, 23740.00%
30 Sep, 235150.00%
30 Jun, 232-60.00%
31 Mar, 235-37.50%
31 Dec, 228166.67%
30 Sep, 223-57.14%
30 Jun, 22716.67%
31 Mar, 22650.00%
31 Dec, 21433.33%
30 Sep, 213-25.00%
30 Jun, 214-66.67%
31 Mar, 2112200.00%
31 Dec, 204-20.00%
30 Sep, 205-
30 Jun, 205-
31 Mar, 20--

7 institutional shareholders have reduced their position in APVO stock as of 31 Dec 23 compared to 5 in the previous quarter (a 40.00% increase).

All Institutional Ownership Trend Data

DateHoldingsChange %Shares OutstandingChange %Ownership %Change %Increased PositionsChange %Reduced PositionsChange %
31 Dec, 233015.38%1,933,445-43.29%15.37%0.56%1233.33%740.00%
30 Sep, 232613.04%3,409,316267.07%52.60%30.06%950.00%5150.00%
30 Jun, 2323-928,8045.35%13.23%8.39%6-14.29%2-60.00%
31 Mar, 2323-11.54%881,596-8.48%12.55%3.52%7-46.15%5-37.50%
31 Dec, 222630.00%963,25011.08%18.89%6.51%1344.44%8166.67%
30 Sep, 2220-867,1499.03%17.03%6.80%9-3-57.14%
30 Jun, 222017.65%795,3370.40%15.83%6.15%950.00%716.67%
31 Mar, 2217-5.56%792,1904.13%16.04%6.09%6-25.00%650.00%
31 Dec, 2118-14.29%760,799-75.57%16.23%0.40%8-20.00%433.33%
30 Sep, 2121-16.00%3,114,1055.20%63.66%1.50%10-23.08%3-25.00%
30 Jun, 2125-24.24%2,960,2220.56%65.25%1.47%13-13.33%4-66.67%
31 Mar, 2133-2.94%2,943,8531.18%66.63%1.54%15-44.44%12200.00%
31 Dec, 2034100.00%2,909,605341.29%65.85%15.83%27237.50%4-20.00%
30 Sep, 2017-10.53%659,3484.30%20.40%5.33%8-11.11%5-
30 Jun, 201918.75%632,18430.45%19.56%8.90%9-43.75%5-
31 Mar, 2016-484,601-14.82%-16---

Aptevo Therapeutics Insider Shareholders Trades


Open Market Insider Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource

Open Market Insider Buys

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource

Insider Sells

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Mar 05, 2024Taylor Daphneofficer SVP, CFOM-ExemptSell3,667--7,333
Mar 05, 2024Taylor Daphneofficer SVP, CFOM-ExemptSell1,584--1,583
Mar 05, 2024Lamothe Jeffrey G.officer EVP, COOM-ExemptSell5,500--11,000
Mar 05, 2024Lamothe Jeffrey G.officer EVP, COOM-ExemptSell3,667--3,667
Mar 05, 2024Kwon SoYoungofficer SVP, GC, BD & Corp AffairsM-ExemptSell3,667--7,333
Mar 05, 2024Kwon SoYoungofficer SVP, GC, BD & Corp AffairsM-ExemptSell3,667--3,667
Mar 05, 2024White Marvin Ldirector, officer President and CEOM-ExemptSell12,917--25,833
Mar 05, 2024White Marvin Ldirector, officer President and CEOM-ExemptSell9,584--9,584
Jan 30, 2024Taylor Daphneofficer SVP, CFOM-ExemptSell792---
Jan 30, 2024Lamothe Jeffrey G.officer EVP, COOM-ExemptSell1,833---

All Insider Owners Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Mar 05, 2024Taylor Daphneofficer SVP, CFOM-ExemptBuy1,584-$1.5818,411
Mar 05, 2024Taylor Daphneofficer SVP, CFOM-ExemptBuy3,667-$3.6716,827
Mar 05, 2024Taylor Daphneofficer SVP, CFOM-ExemptSell3,667--7,333
Mar 05, 2024Taylor Daphneofficer SVP, CFOM-ExemptSell1,584--1,583
Mar 05, 2024Lamothe Jeffrey G.officer EVP, COOM-ExemptBuy3,667-$3.6737,504
Mar 05, 2024Lamothe Jeffrey G.officer EVP, COOM-ExemptBuy5,500-$5.5033,837
Mar 05, 2024Lamothe Jeffrey G.officer EVP, COOM-ExemptSell5,500--11,000
Mar 05, 2024Lamothe Jeffrey G.officer EVP, COOM-ExemptSell3,667--3,667
Mar 05, 2024Kwon SoYoungofficer SVP, GC, BD & Corp AffairsM-ExemptBuy3,667-$3.6724,042
Mar 05, 2024Kwon SoYoungofficer SVP, GC, BD & Corp AffairsM-ExemptBuy3,667-$3.6720,375
Mar 05, 2024Kwon SoYoungofficer SVP, GC, BD & Corp AffairsM-ExemptSell3,667--7,333
Mar 05, 2024Kwon SoYoungofficer SVP, GC, BD & Corp AffairsM-ExemptSell3,667--3,667
Mar 05, 2024White Marvin Ldirector, officer President and CEOM-ExemptBuy9,584-$9.5867,430
Mar 05, 2024White Marvin Ldirector, officer President and CEOM-ExemptBuy12,917-$12.9257,846
Mar 05, 2024White Marvin Ldirector, officer President and CEOM-ExemptSell12,917--25,833
Mar 05, 2024White Marvin Ldirector, officer President and CEOM-ExemptSell9,584--9,584
Jan 30, 2024Taylor Daphneofficer SVP, CFOM-ExemptBuy792-$0.7913,160
Jan 30, 2024Taylor Daphneofficer SVP, CFOM-ExemptSell792---
Jan 30, 2024Lamothe Jeffrey G.officer EVP, COOM-ExemptBuy1,833-$1.8328,337
Jan 30, 2024Lamothe Jeffrey G.officer EVP, COOM-ExemptSell1,833---

The last insider sell of Aptevo Therapeutics's stock was made by Taylor Daphne on Mar 05 2024, selling 3,667 shares at - per share (valued at -).

Aptevo Therapeutics Insider Ownership Trends


All Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q1 20241111100.00%
Q3 202399100.00%
Q2 2023116183.33%
Q1 20231412116.67%
Q3 20229--
Q2 202274175.00%
Q1 20229--
Q4 202131717.65%
Q2 202114--
Q1 20216--
Q4 202016--
Q3 2020264360.47%
Q1 20206--
Q4 20196--
Q3 201911--
Q2 201915--
Q1 20191210120.00%
Q4 20182--
Q3 20181205.00%
Q2 201872350.00%

11 total buy trades, and 11 total sell trades (buy/sell ratio of 1.00%) were made by Aptevo Therapeutics's insiders, as of Q1 2024.

Open Market Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q1 2024---
Q3 2023---
Q2 2023---
Q1 2023---
Q3 2022---
Q2 2022---
Q1 2022---
Q4 2021-17-
Q2 2021---
Q1 2021---
Q4 202016--
Q3 2020---
Q1 2020---
Q4 2019---
Q3 201911--
Q2 20199--
Q1 2019---
Q4 20182--
Q3 2018---
Q2 2018---

As of Q1 2024, Insider owners conducted 0 open market buy trades and 0 open market sell trades of Aptevo Therapeutics's stocks.

Aptevo Therapeutics Peer Ownership


TickerCompany
IVVDInvivyd, Inc.
VRAXVirax Biolabs Group Limited
QNRXQuoin Pharmaceuticals, Ltd.
HOTHHoth Therapeutics, Inc.
MGTADianthus Therapeutics, Inc.
PASGPassage Bio, Inc.
NTRBNutriband Inc.
LGVNLongeveron Inc.
RNXTRenovoRx, Inc.
TCONTRACON Pharmaceuticals, Inc.
REVBRevelation Biosciences, Inc.
NRBONeuroBo Pharmaceuticals, Inc.
LRMRLarimar Therapeutics, Inc.
CYCNCyclerion Therapeutics, Inc.
ACHLAchilles Therapeutics plc
ATXIAvenue Therapeutics, Inc.
ADXNAddex Therapeutics Ltd
KRONKronos Bio, Inc.

APVO Ownership FAQ


Aptevo Therapeutics is owned by institutional shareholders (15.37%), insiders (0.10%), and public (84.53%). The largest institutional shareholder of Aptevo Therapeutics is JPMORGAN CHASE & CO (0% of total shares) and the top mutual fund owner is BRIDGEWAY FUNDS INC (0.03% of total shares).

Aptevo Therapeutics's major institutional shareholders are JPMORGAN CHASE & CO, FIFTH THIRD BANCORP, FRANKLIN RESOURCES INC, BANK OF AMERICA CORP /DE/, and WELLS FARGO & COMPANY/MN. The top five shareholders own together 0% of the company's share outstanding.

As of Dec 2023, there are 30 institutional shareholders of Aptevo Therapeutics.

JPMORGAN CHASE & CO owns 0 shares of Aptevo Therapeutics, representing 0% of the company's total shares outstanding, valued at $0 (as of Mar 2024).

As of Mar 2024, FIFTH THIRD BANCORP holds 0 shares of Aptevo Therapeutics (APVO), compromising 0% of the company, valued at $0.

FRANKLIN RESOURCES INC is the third largest holder of Aptevo Therapeutics. The company owns 0 of the company's shares outstanding (worth $0).